Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ4 | P56696 | 3/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582201 | 0.86 | ALDH1A1 (0.38) | F10MEN1KMT2AHRH3POLB | |
| SCHEMBL16801989 | 0.83 | KCNQ4 (0.41) | KCNQ4KCNQ5CTSLIDO1PTGER1 | |
| SCHEMBL20729391 | 0.80 | NOS2 (0.40) | KCNQ4KCNQ5CTSLIDO1PTGER1 | |
| SCHEMBL20729392 | 0.79 | HSP90AA1 (0.39) | KCNQ4KCNQ5CTSLIDO1PTGER1 | |
| SCHEMBL18104501 | 0.77 | MAPT (0.42) | KCNQ4KCNQ5IDO1PTGER1HSP90AA1 | |
| SCHEMBL20582177 | 0.76 | KDM4E (0.39) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL20729382 | 0.76 | HTT (0.52) | IDO1PTGER1HSP90AA1HSP90AB1F10 | |
| SCHEMBL21734883 | 0.75 | IDO1 (0.44) | IDO1PTGER1HSP90AA1HSP90AB1CYP2C9 | |
| SCHEMBL31718056 | 0.74 | SLC6A4 (0.43) | IDO1PTGER1HSP90AA1HSP90AB1CYP2C9 | |
| SCHEMBL16799845 | 0.74 | SLC6A4 (0.43) | IDO1PTGER1HSP90AA1HSP90AB1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247037-B2 | 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders | Neumora Therapeutics, Inc. (US) | 2025-03-11 | — | — | US | disclosed |
| EP-3894414-B1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | NEUMORA THERAPEUTICS INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230093235-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2023-03-23 | — | — | US | disclosed |
| US-20230084719-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3634963-B1 | 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS FOR TREATING NEUROPSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| WO-2020123872-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | KCNQ4 822/4885KCNQ5 764/4885CTSL 2347/4885 |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1B, AVPR1A, AVPR2 | KCNQ4 822/4885KCNQ5 764/4885CTSL 2347/4885 |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | KCNQ4 822/4885KCNQ5 764/4885CTSL 2347/4885 |
| US-12247037-B2 | 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders | AVPR1B, AVPR1A, AVPR2 | KCNQ4 972/4885KCNQ5 955/4885CTSL 4084/4885 |
| US-20230093235-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1B, AVPR1A, AVPR2 | KCNQ4 822/4885KCNQ5 764/4885CTSL 2347/4885 |
| US-20230084719-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | AVPR1B, AVPR1A, AVPR2 | KCNQ4 634/4885KCNQ5 645/4885CTSL 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.